Fig. 8From: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell linesEffects of EGF, cetuximab, trastuzumab and afatinib treatment on caspase 3 activation. MKN1 and Hs746T cells were treated with EGF, EGFâ+âcetuximab (EGFâ+âCet), cetuximab (Cet), trastuzumab (Tra), afatinib (Afa) or trastuzumab + afatinib (Traâ+âAfa) for 24âh. MKN7 and NCI-N87 were treated with trastuzumab (Tra), afatinib (Afa) or trastuzumab + afatinib (Traâ+âAfa) for 24âh. Cell lysates were analyzed by western blot with antibodies against cleaved (cl.) caspase 3 (Asp175). The mean of three biological experiments with standard deviation is shown. Significant effects compared to untreated are indicated by *p <â0.05 (one-sample t-test). Full-length blots are presented in Additional file 5Back to article page